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Abstract: Breast Cancer is one of the earliest detected neoplasm’s in human beings. Present study comprises all those 
patients of cancer breast of all stages who attended the outdoor department and admitted in indoor wards of department 
of Biochemistry and Surgery of Hospital (Swami Vivekanand Subharti University) attached to Subharti Medical College, 
Meerut. All these patients were clinically evaluated completely by history, clinical examination and various invasive and 
noninvasive investigations to establish the diagnosis and find out the extent of disease in the body. 4.69% & 45.31% of 
the breast cancer patients were pre- & postmenopausal respectively. Maximum patients were found to be in stage III 
(37.5% & 26.56% of pre- & postmenopausal, respectively). 30.8% of premenopausal patients had an ER receptor 
positive tumour. The percentage of such patients in postmenopausal group was 61.1%. Most of the tumours in 
postmenopausal females were ER positive. 28.13% of premenopausal and 21.88% of postmenopausal patients had >3 
lymph nodes affected. Peripheral PSA levels were observed at the time of diagnosis, in relation to stage, lymph node 
status, menopausal status, ER/PR status and flow cytometry. After treatment the PSA level were not different from 
pretreatment levels. During follow up the peripheral PSA levels showed no correlation with recurrence. 
Keywords: Premenopausal, Postmenopausal, Prostate-specific antigen, Estrogen receptor. 
  
INTRODUCTION 
Breast Cancer is one of the earliest detected 
neoplasm’s in human beings with references dating 
back to 525 BC. It is now the commonest malignancy in 
females in Delhi & Mumbai, while overall; it is second 
only to Cancer of Uterine Cervix in Indian ladies.  
 
While increasing hygiene and improved 
healthcare facilities have helped control the viral 
infections that lead to cervical cancer, changing urban 
lifestyles are believed to be behind the increase in breast 
cancer [1]. 
 
Prostate specific Antigen (PSA) a well-
established tumour marker for prostate cancer, is now 
believed to be not prostate specific, but present in other 
tissues as well. It is present in female tissues, 
predominantly the breast and its secretions and can be 
used as a predictive indicator for prognosis, diagnostic 
and treatment. 
 
PSA is a 33kDa glycoprotein, and is a member 
of the human glandular kallikrein family, a locus of 
which is comprised to three genes and spans a 60-70kb 
region on chromosome 19q 13.3-q 13.4 [2, 3]. 
 
Low concentrations of PSA normally released 
in the blood. The clinical utility of PSA as a marker for 
prostate cancer emerged in 1980 with the initial report 
of elevated PSA levels in serum of prostate cancer 
patients [4, 5].  
 
PSA immunoreactivity in breast cancer 
cystolic extract was first identified in 1994 [6-8]. 
Recent studies with ultrasensitive immunoassays 
demonstrated that approximately 70% of  breast tumour 
cystolic extracts contained PSA [9]. Molecular analysis 
verified that the mRNA of breast tumour PSA was 
identified to prostatic PSA [10]. 
 
The fact that not all breast tumours produce 
PSA prompted studies of the utilization of PSA as a 
prognostic indicator in breast cancer. PSA positivity, 
low cellularity, diploid tumours, low S-phase fraction, 
less advanced disease stage, lower risk of relapse and 
longer overall survival [9, 11].  
 
Steroid hormone receptors are favourable 
prognostic indicators in breast cancer, and receptor 
positive patients respond favourable to endocrine 
treatment. It has been found that among the steroid 
hormone receptor positive patients, the presence or 
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absence of PSA has no additional prognostic 
significance. However, in steroid hormone receptor 
negative patients, those with PSA positive tumours 
trend to have a reduced risk of relapse. This finding is 
supported by an observation in which two patients 
ovarian cancer metastatic from a breast primary were 
described. One of the patients, whose ovarian tumour 
was receptor positive and PSA negative, died soon after 
the administration of adjuvant therapy. The other, with 
a steroid hormone receptor negative but PSA positive 
tumour had a good response to adjuvant treatment and 
excellent disease free survival [11, 12]. 
 
The studies for PSA as biological marker in 
breast cancer are very few, and there is enough 
opportunity to explore this marker in relation to 
diagnosis and prognosis of breast carcinoma. The 
present study was, therefore, undertaken to assess if 
peripheral serum PSA levels can be correlated with 
diagnosis and prognosis of breast cancer. 
 
MATERIALS & METHODS 
Present study was held in the department of 
Biochemistry and Surgery of Hospital (Swami 
Vivekanand Subharti University) attached to Subharti 
Medical College, Meerut. It comprises all those patients 
of cancer breast of all stages who attended the outdoor 
department and admitted in indoor wards of this 
hospital. 
 
All these patients were clinically evaluated 
completely by history, clinical examination and various 
invasive and noninvasive investigations to establish the 
diagnosis and find out the extent of disease in the body. 
All the findings were mentioned in the pretested 
perfoma. 
 
27 premenopausal and 16 postmenopausal 
women were studied as control patient on sex and age 
match to establish the standard value of PSA. These 
control patients include all those who were admitted in 
the department of surgery of this hospital for treatment 
of diseases other than any tumour. 
 
Groups classified as- 
A. The cases who did not receive any treatment in 
the past(Untreated or fresh case) 
B. Cases who had received any type of treatment 
in past i.e., before attending outdoor of this 
hospital (previously treated patients) either by 
Surgery, Chemotherapy, Radiotherapy and 
combnation of above treatment modalities 
 
Detailed information from these patients about 
the status of disease before any treatment, type and 
duration of these treatments and response were noted 
down. Base line value of PSA was estimated in both 
group A and B patients. 
 
             Patients admitted (Both of Group A and B) 
were treated according to treatment protocol for 
different stages. The serum PSA values of Breast cancer 
patients were estimated within less than 1 month prior 
to surgery or start of chemotherapy. They were then 
followed up with 3 month serum PSA estimation. The 
patients with inoperable carcinoma breast were 
subjected to random serum PSA estimation which was 
then followed up at 3 monthly intervals. The serum 
PSA of controls was also measured from a random 
sample of blood. 
 
Various other parameters detecting the 
prognosis of disease were also noted in patients with 
carcinoma breast. The patients with carcinoma were 
staged according to the American Joint Committee on 
Cancer (AJCC) system 1992. This system is based on 
clinical examination of tumour(T), lymph nodes(N) and 
metastasis(M) i.e., TNM system.  
 
The samples were collected in especially 
designed clot activator vials & the samples were taken 
immediately to the Department of Biochemistry, 
Subharti Medical College, Meerut for PSA analysis. 
PSA were assayed by two step enzyme immunoassay 
sandwich method with a final fluorescent detection 
(ELFA). Parameter was estimated by following the 




The present study was carried out on 64 
patients clinically diagnosed for Breast Cancer 
attending the Department of Surgery, OPD/admitted in 
the ward of Subharti Hospital, Meerut from December 
2009 to 2010. 
 
The samples were collected in especially 
designed clot activator vials & the samples were taken 
immediately to the Department of Biochemistry, 
Subharti Medical College, Meerut for PSA analysis. 
 
The most common stage at presentation in 
premenopausal ladies was stage IIIB (21.87%). Same 
pattern was observed among the postmenopausal 
patients (14.06%). 
 
Stage III alone constituted the commonest 
stage at presentation (37.5% in premenopausal females 
and 26.56 % in postmenopausal patients) reflecting that 
still the patients tend to ignore the presence of disease 
and present late. 
 
The least common stage in both 
premenopausal and postmenopausal patients is stage I 
(3.1% and 1.56% respectively) (Table 1). 
 
The control group (consisting of patients of 
diseases other than Breast or any other Cancer) was 
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found to be having same serum PSA value (<0.04ng/ml) 
irrespective of their menopausal status (Table 2). 
 
Mean PSA value in serum was found to be 
same in all patients belonging to different tumour stages 
at presentation. No difference was observed in the 
serum PSA level in patients with tumours of different 
stages at presentation (Table 3). 
 
The mean serum PSA level did not have any 
correlation with the number of lymph nodes either pre 
or postmenopausal breast cancer patients (Table 4). 
 
The post-surgery values in this table depict the 
first value measured 3 months after the surgery. The 
healthy women have serum PSA value <0.04ng/ml 
irrespective of their age. The serum PSA levels of 
breast cancer patients was equal to controls (i.e., 
<0.04ng/ml) and this value remained unchanged after 
surgery as well (Table 5). 
 
Administration of Anterior chemotherapy did 
not have any effect on serum PSA values. The values 
remained the same and were similar to the values in 
controls (Table 6). 
 
The serum PSA level failed to show any 
correlation with any of the variables listed in table 7. 
 
Table 1:  Distribution of patients according to stages and menopausal status 
Menstrual cycle No. of 
Patients (%) 
Stage 
  I(%) IIA(%) IIB(%) IIIA(%) IIIB(%) IV(%) 
Pre menopausal 35(54.69) 2(3.1) 3(4.69) 2(3.1) 10(15.62) 14(21.87) 4(6.25) 
Post menopausal 29(45.31) 1(1.56) 2(3.1) 4(6.25) 8(12.5) 9(14.06) 5(7.81) 
Total(%) 64(100) 3(4.68) 5(7.81) 6(9.37) 18(28.12) 23(35.93) 9(14.06) 
 
Table 2: PSA levels in Control Groups 
Menopausal Status No. of Patients (%) Mean PSA value (ng/ml) 
Premenopausal 27 0.034 
Postmenopausal 16 0.035 
 
Table 3: PSA values according to stages in Pre- & Postmenopausal patients 
Stage No. of Patients 
(Pre-menopause) (%) 
No. of Patients 
(Post-menopause) (%) 
Mean PSA value(ng/ml) 
I 2(3.1) 1 (1.56) 0.02 
IIA 3(4.69) 2 (3.1) 0.023 
IIB 2(3.1) 4 (6.25) 0.011 
IIIA 10(15.62) 8 (12.5) 0.012 
IIIB 14(21.87) 9 (14.06) 0.022 
IV 4(6.25) 5 (7.81) 0.03 
Total (%) 35(54.69) 29 (45.31)  
 
Table 4: Value of PSA (ng/ml) with No. of lymph Nodes in different stages in Pre and post-menopausal women 
Stage LN in premenopausal women LN in postmenopausal women 
 No LN <3LN >3LN No LN <3LN >3LN 
I N=1 
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Table 5: PSA concentration in serum of healthy women, breast cancer patients, before and after surgery 
Sample No. of patients Mean Serum PSA value 
(ng/ml) 
Serum of Healthy women 











Serum of breast cancer 
patients before surgery 













Serum of breast cancer 
patients post-surgery 














Table 6: Comparison of PSA and DNA index in Pre- & Postmenopausal women 
Stage No. of Patients Ploidy Mean PSA ng/ml 
  <1 >1  
I     
IIA     
IIB 1(Both)  +(Both) 0.023 
IIIA 1(Premenopause) +(Premenopause)  0.025 
IIIB 1(Both)  +(Both) 0.031 
IV 1(Premenopause)  +(Premenopause) 0.022 
Tx     
 
Table 7: Association between PSA and Clinico-pathological variables 
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Study was performed in the Department of 
Biochemistry & Department of Surgery, Subharti 
Medical College, Meerut.  
 
We included 64 carcinoma breast patients in 
our study. 27 patients of premenopausal state and 16 of 
postmenopausal state admitted to this hospital having 
disease other than cancer act as control groups. Values 
of Prostate Specific Antigen in the serum of patients 
and of control group was found to be <0.04ng/ml. 
 
The patients of carcinoma breast were divided 
into two main groups i.e., premenopausal and 
postmenopausal. They were further classified according 
to UICC system. 
 
According to Stages, the distribution of 
patients was as follows- 
 
In Premenopausal state 3.1% were of stage I 
disease, 4.69% of stage IIA, 3.1% of stage IIB, 15.62% 
of stage IIIA, 21.87% in stage IIIB and 6.25% were of 
stage IV disease. 
 
Among the postmenopausal state 1.56% were 
of stage I disease, 3.1% of stage IIA, 6.25% stage IIB, 
12.5% of stage IIIA, 14.06% of stage IIIB and 7.81% 
were of stage IV. 
 
In our study, most of the patients were found 
to be in stage III (Stage IIIA and IIIB) and in stage IV, 
both in premenopausal as well as postmenopausal 
groups. 
 
We have estimated the level of serum PSA in 
patients of breast cancer and also in age matched 
controls in both pre and postmenopausal groups. The 
PSA levels in breast cancer patients as well as in 
controls were found to be identical (i.e., <0.04ng/ml) 
irrespective of their menopausal status. Thus the PSA 
level in serum failed to show any diagnostic value in 
cancer breast. 
 
Lehrer S et al. [13] proposed that PSA is a 
secreted gene product which can accumulate within the 
tumour milleu, and may eventually enter the circulation. 
PSA thus released into serum may be easily measurable 
diagnostic and prognostic biochemical marker. 
 
The utility of serum PSA as a diagnostic 
marker was, however, questioned by other status. M. 
Giai et al. [15] after a study on two hundred primary 
breast cancer patients status that serum PSA in women 
does not have potential for diagnosis or monitoring. 
Similarly  Romppanen et al. [14], on the basis of a 
prospective case control study involving 2500 women 
which was included 90 histologically confirmed breast 
cancer patients have concluded that serum total PSA 
levels in benign disease and in breast cancer patients are 
not statistically different from those of healthy controls. 
 
The stage of disease failed to show any 
correlation with PSA value in our study. This is 
consistent with the observations of Romppanen et al. 
[15] who observed the values to be having no 
significant difference among controls, breast cancer 
patients and those with benign breast disease. They 
observed that serum total PSA cannot be used to 
distinguish between healthy women and/or women with 
breast cancer or benign breast disease. 
 
Giai M et al. [15] concluded after an extensive 
study that serum PSA levels are not useful for breast 
cancer patient diagnosis or monitoring. However, 
tumour levels of PSA appear to be valuable for breast 
cancer patient prognosis since patients with PSA 
positive tumours have much longer disease free and 
overall survival. This tumour cystolic PSA 
concentration, however, does not seem to influence the 
PSA concentration in the serum of breast cancer 
patients. 
 
Our observations, however, do not support 
those of Diamendis EP et al. [16]. These authors have 
suggested that serum PSA is a potential prognostic 
indicator in breast cancer patients. 
 
No correlation was found to be present 
between the values of PSA in serum of patients in 
different age groups. The values were similar (i.e., 
<0.04ng/ml) in patients and controls of different age 
groups. 
 
The mean serum PSA value was same in 
patients of all tumour grades. This was also the same 
inpatients in both pre as well as postmenopausal groups. 
The grade of tumour, therefore, does not have any 
bearing on the serum total PSA level. 
 
The patients in our study were divided into 
three subgroups according to the number of lymph 
nodes- 
 Patients without lymph nodes 
involvement 
 Patients with <3 lymph nodes 
involved 
 Patients with >3 lymph nodes 
involved 
 
These subgroups were further divided 
according to menopausal status. The value of serum was 
found to be similar in all these subgroups and the serum 
PSA thus failed to correlate with the number of lymph 
nodes in pre as well as postmenopausal patients. 
 
Serum PSA levels were measured in breast 
cancer patients before the starting of definitive therapy, 
and was followed up at 3 monthly intervals. The levels 
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did not show any fall after surgery or chemotherapy, 
nor was any rise in serum PSA level observed as two of 
our patients had relapse. The administration of anterior 
chemotherapy also did not affect the serum PSA values 
and they remained the same before CTx, after CTx and 
after completion of treatment and also in follow up. So 
the serum PSA failed to demonstrate any prognostic 
implication in monitoring of breast cancer patients. 
 
The findings of our study correlate very well 
with study of Giai M et al. in 1995[16]. They observed 
that high levels of tumour PSA were not correlate with 
high PSA levels in the presurgical sera. Serum PSA 
concentration in this study was not higher in patients 
with PSA positive breast cancers than in PSA negative 
cancers. When matched presurgical and postsurgical 
sera were examined, the PSA status in serum did not 
change significantly when the cancer was removed.  
 
Yu H et al. [11] observed in 1995 that after 
adjusting for most of the variables studied, i.e., age, 
clinical stage, tumour size, histological grade, nodal 
status, ER and PR, PSA positive tumours still have a 
significantly decreased risk for relapse when compared 
to PSA negative patients. In contrast, our data did not 
show any correlation with risk of relapse and total 
serum PSA levels. They have further observed that in 
ER positive group, the risk of relapse was almost 
identical between PSA positive and PSA negative 
tumours. However, in the ER negative group, the risk 
for relapse was substantially reduced when the tumours 
were PSA positive. It may therefore, be helpful in 
detecting a subset of ER negative patients who are 
likely to behave favourable to adjuvant therapy and are 
going to have better survival and prognosis. 
 
Our study also did not find any correlation of 
total peripheral PSA and DNA index, or S-phase 
fraction, ER/PR receptor status of the tumour. All these 
indicators are established tumour markers but total PSA 
was not affected by any of these variations. 
 
A few studies have suggested that the serum 
PSA originates from tumours itself. The peripheral PSA 
levels, should therefore, have risen linearly with 
increased in tumour burdon and should have decreased 
with removal of tumour. Our observations do not 
support this hypothesis. Our data are consistent with 
other studies which suggest that serum PSA levels do 
not have any relation with prognosis in breast cancer 
patients, and tumour PSA positivity or negativity does 
not have any bearing on serum PSA levels. 
 
CONCLUSION 
 54.69% of the breast cancer patients were 
premenopausal and 45.31% were 
postmenopausal. 
 Maximum patients were found to be in stage 
III (37.5% of premenopausal and 26.56% of 
postmenopausal). 
 30.8% of premenopausal patients had an ER 
receptor positive tumour. The percentage of 
such patients in postmenopausal group was 
61.1%. 
 Most of the tumours in postmenopausal 
females were ER positive. 
 28.13% of premenopausal and 21.88% of 
postmenopausal patients had >3 lymph nodes 
affected. 
 Peripheral PSA is not an acceptable 
biochemical parameter for the diagnosis, 
reponse to treatment and detection of early 
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